Your browser doesn't support javascript.
loading
Cyclin E2 is the predominant E-cyclin associated with NPAT in breast cancer cells.
Rogers, Samuel; Gloss, Brian S; Lee, Christine S; Sergio, Claudio Marcelo; Dinger, Marcel E; Musgrove, Elizabeth A; Burgess, Andrew; Caldon, Catherine Elizabeth.
Afiliação
  • Rogers S; The Kinghorn Cancer Centre and Cancer Research Program, Garvan Institute of Medical Research, Sydney, NSW Australia.
  • Gloss BS; The Kinghorn Cancer Centre and Cancer Research Program, Garvan Institute of Medical Research, Sydney, NSW Australia ; St Vincent's Clinical School, Faculty of Medicine UNSW, Sydney, Australia.
  • Lee CS; The Kinghorn Cancer Centre and Cancer Research Program, Garvan Institute of Medical Research, Sydney, NSW Australia.
  • Sergio CM; The Kinghorn Cancer Centre and Cancer Research Program, Garvan Institute of Medical Research, Sydney, NSW Australia.
  • Dinger ME; The Kinghorn Cancer Centre and Cancer Research Program, Garvan Institute of Medical Research, Sydney, NSW Australia ; St Vincent's Clinical School, Faculty of Medicine UNSW, Sydney, Australia.
  • Musgrove EA; Wolfson Wohl Cancer Research Centre, University of Glasgow, Garscube Estate, Glasgow, G61 1QH UK.
  • Burgess A; The Kinghorn Cancer Centre and Cancer Research Program, Garvan Institute of Medical Research, Sydney, NSW Australia ; St Vincent's Clinical School, Faculty of Medicine UNSW, Sydney, Australia.
  • Caldon CE; The Kinghorn Cancer Centre and Cancer Research Program, Garvan Institute of Medical Research, Sydney, NSW Australia ; St Vincent's Clinical School, Faculty of Medicine UNSW, Sydney, Australia.
Cell Div ; 10: 1, 2015.
Article em En | MEDLINE | ID: mdl-25741376
ABSTRACT

BACKGROUND:

The cyclin E oncogene activates CDK2 to drive cells from G1 to S phase of the cell cycle to commence DNA replication. It coordinates essential cellular functions with the cell cycle including histone biogenesis, splicing, centrosome duplication and origin firing for DNA replication. The two E-cyclins, E1 and E2, are assumed to act interchangeably in these functions. However recent reports have identified unique functions for cyclins E1 and E2 in different tissues, and particularly in breast cancer.

FINDINGS:

Cyclins E1 and E2 localise to distinct foci in breast cancer cells as well as co-localising within the cell. Both E-cyclins are found in complex with CDK2, at centrosomes and with the splicing machinery in nuclear speckles. However cyclin E2 uniquely co-localises with NPAT, the main activator of cell-cycle regulated histone transcription. Increased cyclin E2, but not cyclin E1, expression is associated with high expression of replication-dependent histones in breast cancers.

CONCLUSIONS:

The preferential localisation of cyclin E1 or cyclin E2 to distinct foci indicates that each E-cyclin has unique roles. Cyclin E2 uniquely interacts with NPAT in breast cancer cells, and is associated with higher levels of histones in breast cancer. This could explain the unique correlations of high cyclin E2 expression with poor outcome and genomic instability in breast cancer.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2015 Tipo de documento: Article